Dushay is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center. It makes my head spin to think about how much GLP-1s ...

LANSING, Mich. (WLNS) — Michigan is failing to meet the American Lung Association’s standards for preventing and reducing tobacco use, according to a new report. The American Lung Association`s annual ...

More than 1 in 8 American adults are using GLP-1’s for weight loss. Experts say these are the nutritional gaps and side effects that should not to be overlooked. As GLP-1 medications continue to ...

Musk could be consolidating his companies. Musk could be consolidating his companies. is a senior reporter covering technology, gaming, and more. He joined The Verge in 2019 after nearly two years at ...

On the Wednesday, January 28, 2026, episode of The Excerpt podcast: As GLP-1 use surges, lawsuits allege blindness, stomach paralysis and more. USA TODAY Investigative Reporter Austin Fast breaks down ...

A sizable percentage of people using Novo (NVO) and Lilly’s (LLY) GLP-1 drugs may be able to sustain their weight loss effects even months after discontinuing the popular obesity drugs, Reuters ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...

On Thursday, OpenAI announced its investment in neurotech startup Merge Labs, cofounded by its CEO, billionaire Sam Altman. OpenAI will collaborate with the new venture to develop technology to link ...

For women with obesity, GLP-1 medications like Ozempic and Wegovy may help address the metabolic challenges that often intensify during midlife. The hormonal shifts of perimenopause and menopause can ...

WESTFIELD — Westfield High School Assistant Principal Andrew Joseph and Instructional Technology Coordinator Brian Dutko informed the School Committee on Jan. 5 that the pilot program for a new ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...